Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: A consensus document by the Belgian Bone Club

Osteoporosis International

Volumn 21, Issue 10, 2010, Pages 1657-1680

  Body, J J ^a   Bergmann, P ^a   Boonen, S ^b   Boutsen, Y ^c   Devogelaer, J P ^d   Goemaere, S ^e   Kaufman, J M ^e   Rozenberg, S ^f   Reginster, J Y ^g  

^a BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e GHENT UNIVERSITY   (Belgium)

^f UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^g UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Bisphosphonate; Osteoporosis; Raloxifene; Strontium; Teriparatide

Indexed keywords

ALENDRONIC ACID; BAZEDOXIFENE; CALCIUM; CALCIUM CARBONATE; CALCIUM PHOSPHATE; CATHEPSIN K INHIBITOR; CITRATE CALCIUM; CONJUGATED ESTROGEN; DENOSUMAB; IBANDRONIC ACID; LASOFOXIFENE; MEDROXYPROGESTERONE ACETATE; ODANACATIB; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE[1-34]; RALOXIFENE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RISEDRONIC ACID; STRONTIUM RANELATE; TAMOXIFEN; TIBOLONE; VITAMIN D; ZOLEDRONIC ACID;

AMNESIA; BELGIUM; CLINICAL TRIAL; CONFERENCE PAPER; CONSENSUS; DIARRHEA; DIZZINESS; DRESS SYNDROME; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; ESOPHAGUS ULCER; EVIDENCE BASED MEDICINE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HOT FLUSH; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; LEG CRAMP; NAUSEA; POSTINFUSION SYNDROME; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; STROKE; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ESTROGEN RECEPTOR MODULATORS; ESTROGEN REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; THIOPHENES;

EID: 77956403362     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1223-4     Document Type: Conference Paper

References (158)

1. SR Cummings DM Black SM Rubin 1989 Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women Arch Intern Med 149 2445 2448 1:STN:280:DyaK3c%2FlsFGgsQ%3D%3D 2818106
2. P Autier P Haentjens J Bentin JM Baillon AR Grivegnee MC Closon S Boonen 2000 Costs induced by hip fractures: a prospective controlled study in Belgium Belgian Hip Fracture Study Group. Osteoporos Int 11 373 380 1:STN:280: DC%2BD3cvgvFeltg%3D%3D
3. A Cranney P Tugwell G Wells G Guyatt 2002 Meta-analyses of therapies for postmenopausal osteoporosis. I. Systematic reviews of randomized trials in osteoporosis: introduction and methodology Endocr Rev 23 496 507 12202464
4. JA Kanis N Burlet C Cooper PD Delmas JY Reginster F Borgstrom R Rizzoli 2008 European guidance for the diagnosis and management of osteoporosis in postmenopausal women Osteoporos Int 19 399 428 1:STN:280:DC%2BD1c3itFekuw%3D%3D 18266020
5. S Boonen JJ Body Y Boutsen JP Devogelaer S Goemaere JM Kaufman S Rozenberg JY Reginster 2005 Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club Osteoporos Int 16 239 254 15726235
6. JA Kanis N Burlet C Cooper PD Delmas JY Reginster F Borgstrom R Rizzoli European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) 2008 European guidance for the diagnosis and management of osteoporosis in postmenopausal women Osteoporos Int 19 399 428 1:STN:280:DC%2BD1c3itFekuw%3D%3D 18266020
7. A Neuprez H Johansson JA Kanis EV McCloskey A Oden O Bruyere M Hiligsmann JP Devogelaer JM Kaufman JY Reginster 2009 Rationalisation du remboursement des médicaments de l'ostéoporose : de la mesure isolée de la densité osseuse à l'intégration des facteurs cliniques de risque fracturaire. Validation de l'algorithme FRAX® Rev Med Liege 64 612 619 1:STN:280:DC%2BC3c%2Fps12gtw%3D%3D 20143744
8. R Rizzoli S Boonen ML Brandi N Burlet P Delmas JY Reginster 2008 The role of calcium and vitamin D in the management of osteoporosis Bone 42 246 249 1:CAS:528:DC%2BD1cXls1eiuw%3D%3D 18055288
9. S Boonen HA Bischoff-Ferrari C Cooper P Lips O Ljunggren PJ Meunier JY Reginster 2006 Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: a review of the evidence Calcif Tissue Int 78 257 270 1:CAS:528:DC%2BD28XksFSgsrc%3D 16622587
10. NIH Consensus conference 1994 Optimal calcium intake. NIH consensus development panel on optimal calcium intake JAMA 272 1942 1948
11. SD Thomas AG Need G Tucker P Slobodian PD O'Loughlin BE Nordin 2008 Suppression of parathyroid hormone and bone resorption by calcium carbonate and calcium citrate in postmenopausal women Calcif Tissue Int 83 81 84 1:CAS:528:DC%2BD1cXhtVyju7fF 18553042
12. X Deprez P Fardellone 2003 Nonpharmacological prevention of osteoporotic fractures Joint Bone Spine 70 448 457 14667552
13. Lips P, Bouillon R, van Schoor N, Vanderschueren D, Verschueren S, Kuchuk N, Milisen K, Boonen S (2009) Reducing fracture risk with calcium and vitamin D. Clin Endocrinol. doi: 10.1111/j.0300-0664.2009.03701.x
14. MC Chapuy ME Arlot F Duboeuf J Brun B Crouzet S Arnaud PD Delmas PJ Meunier 1992 Vitamin D3 and calcium to prevent hip fractures in the elderly women N Engl J Med 327 1637 1642 1:STN:280:DyaK3s%2FmtlSrug%3D%3D 1331788
15. MC Chapuy ME Arlot PD Delmas PJ Meunier 1994 Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women BMJ 308 1081 1082 1:STN:280:DyaK2c3islKnuw%3D%3D 8173430
16. MC Chapuy R Pamphile E Paris C Kempf M Schlichting S Arnaud P Garnero PJ Meunier 2002 Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study Osteoporos Int 13 257 264 1:CAS:528:DC%2BD38XksVynt7g%3D 11991447
17. B Dawson-Hughes SS Harris EA Krall GE Dallal 1997 Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older N Engl J Med 337 670 676 1:CAS:528:DyaK2sXmt1Wqtbk%3D 9278463
18. P Lips WC Graafmans ME Ooms PD Bezemer LM Bouter 1996 Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial Ann Intern Med 124 400 406 1:STN:280:DyaK287ltF2nsQ%3D%3D 8554248
19. DP Trivedi R Doll KT Khaw 2003 Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial BMJ 326 469 1:CAS:528:DC%2BD3sXisFart7Y%3D 12609940
20. RJ Heikinheimo JA Inkovaara EJ Harju MV Haavisto RH Kaarela JM Kataja AM Kokko LA Kolho SA Rajala 1992 Annual injection of vitamin D and fractures of aged bones Calcif Tissue Int 51 105 110 1:CAS:528:DyaK38XlvVCltrc%3D 1422948
21. HA Bischoff-Ferrari WC Willett JB Wong E Giovannucci T Dietrich B Dawson-Hughes 2005 Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials JAMA 293 2257 2264 1:CAS:528:DC%2BD2MXktFOntb8%3D 15886381
22. S Boonen P Lips R Bouillon HA Bischoff-Ferrari D Vanderschueren P Haentjens 2007 Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials J Clin Endocrinol Metab 92 1415 1423 1:CAS:528:DC%2BD2sXksVSrt7k%3D 17264183
23. HA Bischoff-Ferrari WC Willett JB Wong AE Stuck HB Staehelin EJ Orav A Thoma DP Kiel J Henschkowski 2009 Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials Arch Intern Med 169 551 561 1:CAS:528:DC%2BD1MXksVOntr4%3D 19307517
24. BM Tang GD Eslick C Nowson C Smith A Bensoussan 2007 Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis Lancet 370 657 666 1:CAS:528:DC%2BD2sXpsFWrsbc%3D 17720017
25. S Adami G Isaia G Luisetto S Minisola L Sinigaglia R Gentilella D Agnusdei N Iori R Nuti 2006 Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study J Bone Miner Res 21 1565 1570 1:CAS:528:DC%2BD28XhtFekt7zN 16995811
26. M Rossini G Bianchi O Di Munno S Giannini S Minisola L Sinigaglia S Adami 2006 Determinants of adherence to osteoporosis treatment in clinical practice Osteoporos Int 17 914 921 1:STN:280:DC%2BD283osVKltg%3D%3D 16538553
27. S Rozenberg J Vandromme M Kroll A Pastijn M Degueldre 1994 Osteoporosis prevention with sex hormone replacement therapy Int J Fertil Menopausal Stud 39 262 271 1:STN:280:DyaK2M7itVShsQ%3D%3D 7820159
28. JE Rossouw GL Anderson RL Prentice AZ LaCroix C Kooperberg ML Stefanick RD Jackson SA Beresford BV Howard KC Johnson JM Kotchen J Ockene 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 321 333 1:CAS:528:DC%2BD38Xltlegs7k%3D 12117397
29. PY Scarabin E Oger G Plu-Bureau 2003 Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk Lancet 362 428 432 1:CAS:528:DC%2BD3sXmt1ajsr0%3D 12927428
30. M Canonico E Bouaziz L Carcaillon C Verstuyft A Guiochon-Mantel L Becquemont PY Scarabin Estrogen and Thromboembolism Risk (ESTHER) Study Group 2008 Synergism between oral estrogen therapy and cytochrome P450 3A5 1 allele on the risk of venous thromboembolism among postmenopausal women J Clin Endocrinol Metab 93 3082 3087 1:CAS:528:DC%2BD1cXpvVOlsrg%3D 18628519
31. SR Cummings B Ettinger PD Delmas P Kenemans V Stathopoulos P Verweij M Mol-Arts L Kloosterboer L Mosca C Christiansen J Bilezikian EM Kerzberg S Johnson J Zanchetta DE Grobbee W Seifert R Eastell 2008 The effects of tibolone in older postmenopausal women N Engl J Med 359 697 708 1:CAS:528: DC%2BD1cXpvFyksL0%3D 18703472
32. A Gompel S Rozenberg DH Barlow 2008 The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy Maturitas 61 227 232 1:CAS:528:DC%2BD1cXhsVeru7rN 19028033
33. I Lekander F Borgström O Ström N Zethraeus JA Kanis 2009 Cost-effectiveness of hormone therapy in the United States J Womens Health (Larchmt) 10 1669 1677
34. YZ Bagger LB Tanko P Alexandersen HB Hansen A Mollgaard P Ravn P Qvist JA Kanis C Christiansen 2004 Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study Bone 34 728 735 1:CAS:528:DC%2BD2cXisF2ntb0%3D 15050905
35. P Alexandersen A Toussaint C Christiansen JP Devogelaer C Roux J Fechtenbaum C Gennari JY Reginster 2001 Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial JAMA 285 1482 1488 1:CAS:528:DC%2BD3MXis1CjsLg%3D 11255425
36. DL Alekel AS Germain CT Peterson KB Hanson JW Stewart T Toda 2000 Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women Am J Clin Nutr 72 844 852 1:CAS:528:DC%2BD3cXmsFGrt7Y%3D 10966908
37. CS Hsu WW Shen YM Hsueh SL Yeh 2001 Soy isoflavone supplementation in postmenopausal women. Effects on plasma lipids, antioxidant enzyme activities and bone density J Reprod Med 46 221 226 1:CAS:528:DC%2BD3MXjtVOhurs%3D 11304862
38. YM Chen SC Ho SS Lam SS Ho JL Woo 2003 Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial J Clin Endocrinol Metab 88 4740 4747 1:CAS:528:DC%2BD3sXoslemt7Y%3D 14557449
39. S Kreijkamp-Kaspers L Kok DE Grobbee EH de Haan A Aleman JW Lampe YT van der Schouw 2004 Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial JAMA 292 65 74 1:CAS:528:DC%2BD2cXls1elsL8%3D 15238592
40. E Nikander M Metsa-Heikkila O Ylikorkala A Tiitinen 2004 Effects of phytoestrogens on bone turnover in postmenopausal women with a history of breast cancer J Clin Endocrinol Metab 89 1207 1212 1:CAS:528:DC%2BD2cXisVWru74%3D 15001611
41. E Seeman GG Crans A Diez-Perez KV Pinette PD Delmas 2006 Anti-vertebral fracture efficacy of raloxifene: a meta-analysis Osteoporos Int 17 313 316 16217588
42. RR Recker D Kendler CP Recknor TW Rooney EM Lewiecki WH Utian JA Cauley J Lorraine Y Qu PM Kulkarni CL Gaich M Wong L Plouffe Jr JL Stock 2007 Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass Bone 40 843 851 1:CAS:528: DC%2BD2sXjtVaktrk%3D 17182297
43. S Martino JA Cauley E Barrett-Connor TJ Powles J Mershon D Disch RJ Secrest SR Cummings 2004 Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 96 1751 1761 1:CAS:528:DC%2BD2cXhtVCrsrjM 15572757
44. ES Siris ST Harris R Eastell JR Zanchetta S Goemaere A Diez-Perez JL Stock J Song Y Qu PM Kulkarni SR Siddhanti M Wong SR Cummings 2005 Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study J Bone Miner Res 20 1514 1524 1:CAS:528:DC%2BD2MXhtVOltrrP 16059623
45. SJ Neele R Evertz RG De Valk-De JC Roos JC Netelenbos 2002 Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women Bone 30 599 603 1:CAS:528:DC%2BD38XisV2ksb4%3D 11934652
46. E Barrett-Connor L Mosca P Collins MJ Geiger D Grady M Kornitzer MA McNabb NK Wenger 2006 Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 355 125 137 1:CAS:528: DC%2BD28Xmsl2ktrs%3D 16837676
47. VG Vogel JP Costantino DL Wickerham WM Cronin RS Cecchini JN Atkins TB Bevers L Fehrenbacher ER Pajon Jr JL Wade 3rd A Robidoux RG Margolese J James SM Lippman CD Runowicz PA Ganz SE Reis W McCaskill-Stevens LG Ford VC Jordan N Wolmark 2006 Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 295 2727 2741 1:CAS:528: DC%2BD28XmtFOltLc%3D 16754727
48. UA Liberman SR Weiss J Broll HW Minne H Quan NH Bell J Rodriguez-Portales RW Downs Jr J Dequeker M Favus 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The alendronate phase III osteoporosis treatment study group N Engl J Med 333 1437 1443 1:CAS:528:DyaK28XkslehtA%3D%3D 7477143
49. DM Black SR Cummings DB Karpf JA Cauley DE Thompson MC Nevitt DC Bauer HK Genant WL Haskell R Marcus SM Ott JC Torner SA Quandt TF Reiss KE Ensrud 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group Lancet 348 1535 1541 1:CAS:528:DyaK2sXisFCktQ%3D%3D 8950879
50. SR Cummings DM Black DE Thompson WB Applegate E Barrett-Connor TA Musliner L Palermo R Prineas SM Rubin JC Scott T Vogt R Wallace AJ Yates AZ LaCroix 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial JAMA 280 2077 2082 1:CAS:528:DyaK1MXjsVWruw%3D%3D 9875874
51. DB Karpf DR Shapiro E Seeman KE Ensrud CC Johnston Jr S Adami ST Harris AC Santora 2nd LJ Hirsch L Oppenheimer D Thompson 1997 Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate osteoporosis treatment study groups JAMA 277 1159 1164 1:CAS:528:DyaK2sXis1eqsb8%3D 9087473
52. A Cranney G Wells A Willan L Griffith N Zytaruk V Robinson D Black J Adachi B Shea P Tugwell G Guyatt 2002 Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women Endocr Rev 23 508 516 1:CAS:528:DC%2BD38Xnt1Wiur8%3D 12202465
53. HG Bone D Hosking JP Devogelaer JR Tucci RD Emkey RP Tonino JA Rodriguez-Portales RW Downs J Gupta AC Santora UA Liberman 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women N Engl J Med 350 1189 1199 1:CAS:528:DC%2BD2cXit12rsLc%3D 15028823
54. DM Black AV Schwartz KE Ensrud JA Cauley S Levis SA Quandt S Satterfield RB Wallace DC Bauer L Palermo LE Wehren A Lombardi AC Santora SR Cummings 2006 Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial JAMA 296 2927 2938 1:CAS:528:DC%2BD2sXnvVGh 17190893
55. PC de Groen DF Lubbe LJ Hirsch A Daifotis W Stephenson D Freedholm S Pryor-Tillotson MJ Seleznick H Pinkas KK Wang 1996 Esophagitis associated with the use of alendronate N Engl J Med 335 1016 1021 8793925
56. T Schnitzer HG Bone G Crepaldi S Adami M McClung D Kiel D Felsenberg RR Recker RP Tonino C Roux A Pinchera AJ Foldes SL Greenspan MA Levine R Emkey AC Santora 2nd A Kaur DE Thompson J Yates JJ Orloff 2000 Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group Aging (Milano) 12 1 12 1:CAS:528:DC%2BD3cXitVCns7g%3D
57. RJ Dansereau DJ Crail AC Perkins 2009 In vitro disintegration studies of weekly generic alendronate sodium tablets (70 mg) available in the US Curr Med Res Opin 25 449 452 1:CAS:528:DC%2BD1MXltVWms7c%3D 19192989
58. AC Perkins PE Blackshaw PD Hay SC Lawes CT Atherton RJ Dansereau LK Wagner DJ Schnell RC Spiller 2008 Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects Clin Ther 30 834 844 1:CAS:528:DC%2BD1cXhtValsr3J 18555931
59. Ringe JD, Moller G (2009) Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int. doi: 10.1007/s00296-009-0940-5
60. ST Harris NB Watts HK Genant CD McKeever T Hangartner M Keller CH Chesnut 3rd J Brown EF Eriksen MS Hoseyni DW Axelrod PD Miller 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group JAMA 282 1344 1352 1:CAS:528:DyaK1MXmvFansr0%3D 10527181
61. J Reginster HW Minne OH Sorensen M Hooper C Roux ML Brandi B Lund D Ethgen S Pack I Roumagnac R Eastell 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) study group Osteoporos Int 11 83 91 1:CAS:528:DC%2BD3cXhvFGgsr0%3D 10663363
62. NB Watts RG Josse RC Hamdy RA Hughes MD Manhart I Barton D Calligeros D Felsenberg 2003 Risedronate prevents new vertebral fractures in postmenopausal women at high risk J Clin Endocrinol Metab 88 542 549 1:CAS:528: DC%2BD3sXhtlChsLg%3D 12574177
63. JT Harrington LG Ste-Marie ML Brandi R Civitelli P Fardellone A Grauer I Barton S Boonen 2004 Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis Calcif Tissue Int 74 129 135 1:CAS:528:DC%2BD2cXhtFGjt78%3D 14648009
64. OH Sorensen GM Crawford H Mulder DJ Hosking C Gennari D Mellstrom S Pack D Wenderoth C Cooper JY Reginster 2003 Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience Bone 32 120 126 1:CAS:528:DC%2BD3sXhvFWqu7o%3D 12633783
65. S Boonen MR McClung R Eastell G El-Hajj Fuleihan IP Barton P Delmas 2004 Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old J Am Geriatr Soc 52 1832 1839 15507059
66. MR McClung P Geusens PD Miller H Zippel WG Bensen C Roux S Adami I Fogelman T Diamond R Eastell PJ Meunier JY Reginster 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group N Engl J Med 344 333 340 1:CAS:528:DC%2BD3MXht1Wlu7g%3D 11172164
67. A Cranney P Tugwell J Adachi B Weaver N Zytaruk A Papaioannou V Robinson B Shea G Wells G Guyatt 2002 Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis Endocr Rev 23 517 523 1:CAS:528:DC%2BD38Xnt1Wiurs%3D 12202466
68. JP Brown DL Kendler MR McClung RD Emkey JD Adachi MA Bolognese Z Li A Balske R Lindsay 2002 The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis Calcif Tissue Int 71 103 111 1:CAS:528:DC%2BD38Xms1emurY%3D 12085156
69. IC Chesnut A Skag C Christiansen R Recker JA Stakkestad A Hoiseth D Felsenberg H Huss J Gilbride RC Schimmer PD Delmas 2004 Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 19 1241 1249 1:CAS:528: DC%2BD2cXntFGqurw%3D
70. JY Reginster S Adami P Lakatos M Greenwald JJ Stepan SL Silverman C Christiansen L Rowell N Mairon B Bonvoisin MK Drezner R Emkey D Felsenberg C Cooper PD Delmas PD Miller 2006 Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study Ann Rheum Dis 65 654 661 1:CAS:528:DC%2BD28XkvFyqur0%3D 16339289
71. JA Stakkestad P Lakatos R Lorenc F Sedarati C Neate JY Reginster 2008 Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension Clin Rheumatol 27 955 960 18180976
72. PD Delmas S Adami C Strugala JA Stakkestad JY Reginster D Felsenberg C Christiansen R Civitelli MK Drezner RR Recker M Bolognese C Hughes D Masanauskaite P Ward P Sambrook DM Reid 2006 Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study Arthritis Rheum 54 1838 1846 1:CAS:528:DC%2BD28Xms1Sjurs%3D 16729277
73. A Cranney GA Wells E Yetisir S Adami C Cooper PD Delmas PD Miller S Papapoulos JY Reginster PN Sambrook S Silverman E Siris JD Adachi 2009 Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data Osteoporos Int 20 291 297 1:CAS:528: DC%2BD1MXktVSgsQ%3D%3D 18663402
74. ST Harris WA Blumentals PD Miller 2008 Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies Curr Med Res Opin 24 237 245 1:CAS:528:DC%2BD1cXhvVOgtL0%3D 18047776
75. AI Sebba RD Emkey JD Kohles PN Sambrook 2009 Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis Bone 44 423 427 1:CAS:528: DC%2BD1MXhvF2qsb8%3D 19049913
76. ST Harris JY Reginster C Harley WA Blumentals SA Poston CE Barr SL Silverman 2009 Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study Bone 44 758 765 1:CAS:528:DC%2BD1MXktFags7c%3D 19168160
77. S Boonen P Haentjens L Vandenput D Vanderschueren 2004 Preventing osteoporotic fractures with antiresorptive therapy: implications of microarchitectural changes J Intern Med 255 1 12 1:STN:280: DC%2BD2c%2FmsVShtQ%3D%3D 14687233
78. PD Miller S Epstein F Sedarati JY Reginster 2008 Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study Curr Med Res Opin 24 207 213 1:CAS:528:DC%2BD1cXhvVOgtL8%3D 18042311
79. R von Moos CB Caspar B Thurlimann R Angst R Inauen R Greil B Bergstrom K Schmieding M Pecherstorfer 2008 Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study Ann Oncol 19 1266 1270
80. JJ Body IJ Diel MR Lichinitser ED Kreuser W Dornoff VA Gorbunova M Budde B Bergström 2003 Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases Ann Oncol 14 1399 1405 12954579
81. NB Watts C Cooper R Lindsay R Eastell MD Manhart IP Barton TP van Staa JD Adachi 2004 Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk J Clin Densitom 7 255 261 15319494
82. S Boonen D Vanderschueren K Venken K Milisen M Delforge P Haentjens 2008 Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance J Intern Med 264 315 332 1:CAS:528:DC%2BD1cXht1Omt7%2FK 18823505
83. JA Gasser P Ingold A Venturiere V Shen JR Green 2008 Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat J Bone Miner Res 23 544 551 1:CAS:528:DC%2BD1cXltFyhsbg%3D 18072878
84. IR Reid JP Brown P Burckhardt Z Horowitz P Richardson U Trechsel A Widmer JP Devogelaer JM Kaufman P Jaeger JJ Body ML Brandi J Broell R Di Micco AR Genazzani D Felsenberg J Happ MJ Hooper J Ittner G Leb H Mallmin T Murray S Ortolani A Rubinacci M Saaf G Samsioe L Verbruggen PJ Meunier 2002 Intravenous zoledronic acid in postmenopausal women with low bone mineral density N Engl J Med 346 653 661 1:CAS:528:DC%2BD38XhsFOjsrw%3D 11870242
85. MJ Bolland AB Grey AM Horne SE Briggs MG Thomas RB Ellis-Pegler KE Callon GD Gamble IR Reid 2008 Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months J Bone Miner Res 23 1304 1308 1:CAS:528:DC%2BD1cXpvFyiu7c%3D 18627266
86. DM Black PD Delmas R Eastell IR Reid S Boonen JA Cauley F Cosman P Lakatos PC Leung Z Man C Mautalen P Mesenbrink H Hu J Caminis K Tong T Rosario-Jansen J Krasnow TF Hue D Sellmeyer EF Eriksen SR Cummings 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822 1:CAS:528:DC%2BD2sXltVSktLc%3D 17476007
87. RR Recker PD Delmas J Halse IR Reid S Boonen PA Garcia-Hernandez J Supronik EM Lewiecki L Ochoa P Miller H Hu P Mesenbrink F Hartl J Gasser EF Eriksen 2008 Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure J Bone Miner Res 23 6 16 1:CAS:528: DC%2BD1cXhtVCmt7c%3D 17892374
88. KW Lyles CS Colon-Emeric JS Magaziner JD Adachi CF Pieper C Mautalen L Hyldstrup C Recknor L Nordsletten KA Moore C Lavecchia J Zhang P Mesenbrink PK Hodgson K Abrams JJ Orloff Z Horowitz EF Eriksen S Boonen 2007 Zoledronic acid and clinical fractures and mortality after hip fracture N Engl J Med 357 1799 1809 1:CAS:528:DC%2BD2sXht1Kit7nN 17878149
89. Colon-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P, Eriksen E, Magaziner J (2009) Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res. doi: 10.1359/jbmr.090704
90. RR Recker EM Lewiecki PD Miller J Reiffel 2009 Safety of bisphosphonates in the treatment of osteoporosis Am J Med 122 S22 S32 1:CAS:528: DC%2BD1MXjs1KmtLc%3D 19187809
91. YK Loke V Jeevanantham S Singh 2009 Bisphosphonates and atrial fibrillation: systematic review and meta-analysis Drug Saf 32 219 228 1:CAS:528:DC%2BD1MXlvFCmu7k%3D 19338379
92. S Boonen DE Sellmeyer K Lippuner A Orlov-Morozov K Abrams P Mesenbrink EF Eriksen PD Miller 2008 Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women Kidney Int 74 641 648 1:CAS:528: DC%2BD1cXpvVaiurY%3D 18509324
93. D Weycker D Macarios J Edelsberg G Oster 2006 Compliance with drug therapy for postmenopausal osteoporosis Osteoporos Int 17 1645 1652 1:STN:280:DC%2BD28rotlahsA%3D%3D 16862397
94. V Rabenda J Vanoverloop V Fabri R Mertens F Sumkay C Vannecke A Deswaef GA Verpooten JY Reginster 2008 Low incidence of anti-osteoporosis treatment after hip fracture J Bone Joint Surg Am 90 2142 2148 18829912
95. MP Ettinger R Gallagher PE MacCosbe 2006 Medication persistence with weekly versus daily doses of orally administered bisphosphonates Endocr Pract 12 522 528 17002926
96. Cotte FE, Fardellone P, Mercier F, Gaudin AF, Roux C (2010) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21:145-55
97. AA Khan GK Sandor E Dore AD Morrison M Alsahli F Amin E Peters DA Hanley SR Chaudry B Lentle DW Dempster FH Glorieux AJ Neville RM Talwar CM Clokie MA Mardini T Paul S Khosla RG Josse S Sutherland DK Lam RP Carmichael N Blanas D Kendler S Petak LG Ste-Marie J Brown AW Evans L Rios JE Compston 2009 Bisphosphonate associated osteonecrosis of the jaw J Rheumatol 36 478 490 19286860
98. MR Allen DB Burr 2009 The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data J Oral Maxillofac Surg 67 61 70 19371816
99. BA Lenart DG Lorich JM Lane 2008 Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate New Engl J Med 358 1304 1306 1:CAS:528:DC%2BD1cXjvVarsb8%3D 18354114
100. JP Schneider 2009 Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk Geriatrics 64 18 23 19256578
101. AS Neviaser JM Lane BA Lenart F Edobor-Osula DG Lorich 2008 Low-energy femoral shaft fractures associated with alendronate use J Orthop Trauma 22 346 350 18448990
102. EB Kwek SK Goh JS Koh MA Png TS Howe 2008 An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39 224 231 18222447
103. RD Chapurlat M Arlot B Burt-Pichat P Chavassieux JP Roux N Portero-Muzy P Delmas 2007 Microcrack frequency and bone turnover in osteoporotic women on long term bisphosphonates: a bone biopsy study J Bone Miner Res 22 1502 1509 1:CAS:528:DC%2BD2sXhtFyhu7nJ 17824840
104. JJ Stepan DB Burr I Pavo A Sipos D Michalska J Li A Fahrleitner-Pammer H Petto M Westmore D Michalsky M Sato H Dobnig 2007 Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis Bone 41 378 385 17597017
105. B Abrahamsen P Eiken R Eastell 2009 Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study J Bone Miner Res 24 1095 1102 1:CAS:528:DC%2BD1MXmvFyjtrY%3D 19113931
106. DW Dempster F Cosman M Parisien V Shen R Lindsay 1993 Anabolic actions of parathyroid hormone on bone Endocr Rev 14 690 709 1:CAS:528: DyaK2cXmvFKlug%3D%3D 8119233
107. E Canalis A Giustina JP Bilezikian 2007 Mechanisms of anabolic therapies for osteoporosis N Engl J Med 357 905 916 1:CAS:528:DC%2BD2sXpvVylurk%3D 17761594
108. RM Neer CD Arnaud JR Zanchetta R Prince GA Gaich JY Reginster AB Hodsman EF Eriksen S Ish-Shalom HK Genant O Wang BH Mitlak 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 1434 1441 1:CAS:528:DC%2BD3MXktVSgsbw%3D 11346808
109. PD Miller JP Bilezikian M Diaz-Curiel P Chen F Marin JH Krege M Wong R Marcus 2007 Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide J Clin Endocrinol Metab 92 3535 3541 1:CAS:528: DC%2BD2sXhtVGqsrnL 17609307
110. MR McClung J San Martin PD Miller R Civitelli F Bandeira M Omizo DW Donley GP Dalsky EF Eriksen 2005 Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass Arch Intern Med 165 1762 1768 1:CAS:528:DC%2BD2MXpslGgs7c%3D 16087825
111. P Chen JH Satterwhite AA Licata EM Lewiecki AA Sipos DM Misurski RB Wagman 2005 Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis J Bone Miner Res 20 962 970 1:CAS:528:DC%2BD2MXlsFehtr0%3D 15883636
112. H Dobnig A Sipos Y Jiang A Fahrleitner-Pammer LG Ste-Marie JC Gallagher I Pavo J Wang EF Eriksen 2005 Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy J Clin Endocrinol Metab 90 3970 3977 1:CAS:528:DC%2BD2MXmtlCitrg%3D 15840739
113. R Marcus O Wang J Satterwhite B Mitlak 2003 The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis J Bone Miner Res 18 18 23 1:CAS:528:DC%2BD3sXltFKmtQ%3D%3D 12510801
114. B Dawson-Hughes P Chen JH Krege 2007 Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency J Clin Endocrinol Metab 92 4630 4636 1:CAS:528:DC%2BD1cXmslWhtbo%3D 17911178
115. R Lindsay WH Scheele R Neer G Pohl S Adami C Mautalen JY Reginster JJ Stepan SL Myers BH Mitlak 2004 Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis Arch Intern Med 164 2024 2030 15477438
116. DM Black SL Greenspan KE Ensrud L Palermo JA McGowan TF Lang P Garnero ML Bouxsein JP Bilezikian CJ Rosen 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis N Engl J Med 349 1207 1215 1:CAS:528:DC%2BD3sXns1Kmsrw%3D 14500804
117. C Deal M Omizo EN Schwartz EF Eriksen P Cantor J Wang EV Glass SL Myers JH Krege 2005 Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial J Bone Miner Res 20 1905 1911 1:CAS:528:DC%2BD2MXht1amt7nP 16234962
118. B Ettinger J San Martin G Crans I Pavo 2004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate J Bone Miner Res 19 745 751 1:CAS:528:DC%2BD2cXktFGksrk%3D 15068497
119. AB Hodsman DA Hanley MP Ettinger MA Bolognese J Fox AJ Metcalfe R Lindsay 2003 Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis J Clin Endocrinol Metab 88 5212 5220 1:CAS:528:DC%2BD3sXptVyns7k%3D 14602752
120. SL Greenspan HG Bone MP Ettinger DA Hanley R Lindsay JR Zanchetta CM Blosch AL Mathisen SA Morris TB Marriott 2007 Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial Ann Intern Med 146 326 339 17339618
121. JY Reginster O Malaise A Neuprez O Bruyere 2007 Strontium ranelate in the prevention of osteoporotic fractures Int J Clin Pract 61 324 328 1:CAS:528:DC%2BD2sXjs1Wks7w%3D 17263720
122. PJ Meunier C Roux E Seeman S Ortolani JE Badurski TD Spector J Cannata A Balogh EM Lemmel S Pors-Nielsen R Rizzoli HK Genant JY Reginster 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis N Engl J Med 350 459 468 1:CAS:528: DC%2BD2cXos1Snsw%3D%3D 14749454
123. E Canalis M Hott P Deloffre Y Tsouderos PJ Marie 1996 The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro Bone 18 517 523 1:CAS:528:DyaK28Xkslagu7k%3D 8805991
124. R Baron Y Tsouderos 2002 In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation Euro J Pharmacol 450 11 17 1:CAS:528:DC%2BD38XmtlKjsb8%3D
125. N Takahashi T Sasaki Y Tsouderos T Suda 2003 S 12911-2 inhibits osteoclastic bone resorption in vitro J Bone Miner Res 18 1082 1087 1:CAS:528:DC%2BD3sXkslOhsbk%3D 12817762
126. AS Hurtel-Lemaire R Mentaverri A Caudrillier F Cournarie A Wattel S Kamel EF Terwilliger EM Brown M Brazier 2009 The calcium-sensing receptor is involved in strontium ranelate-induced osteoclast apoptosis. New insights into the associated signaling pathways J Biol Chem 284 575 584 1:CAS:528: DC%2BD1cXhsFCjtLjM 18927086
127. E Bonne lye A Chabadel F Saltel P Jurdic 2008 Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro Bone 42 129 138 1:CAS:528:DC%2BD2sXhsVOrtr3E
128. SD Bain C Jerome V Shen I Dupin-Roger P Ammann 2009 Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants Osteoporos Int 20 1417 1428 1:CAS:528: DC%2BD1MXotlyhurg%3D 19096745
129. JY Reginster E Seeman MC De Vernejoul S Adami J Compston C Phenekos JP Devogelaer MD Curiel A Sawicki S Goemaere OH Sorensen D Felsenberg PJ Meunier 2005 Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study J Clin Endocrinol Metab 90 2816 2822 1:CAS:528: DC%2BD2MXkt1Wgt78%3D 15728210
130. JY Reginster T Spector J Badurski 2002 A short-term run-in study can significantly contribute to increasing the quality of long-term osteoporosis trials. The strontium ranelate phase III program Osteoporos Int 13 S30
131. JY Reginster D Felsenberg S Boonen A Diez-Perez R Rizzoli ML Brandi TD Spector K Brixen S Goemaere C Cormier A Balogh PD Delmas PJ Meunier 2008 Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial Arthritis Rheum 58 1687 1695 1:CAS:528:DC%2BD1cXotVOntrg%3D 18512789
132. JY Reginster A Sawicki Roces-Varela 2008 Strontium ranelate: 8 years efficacy on vertebral and nonvertebral fractures in post menopausal osteoporotic women Osteoporos Int 19 S131 S132
133. C Roux JY Reginster J Fechtenbaum S Kolta A Sawicki Z Tulassay G Luisetto JM Padrino D Doyle R Prince P Fardellone OH Sorensen PJ Meunier 2006 Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors J Bone Miner Res 21 536 542 1:CAS:528:DC%2BD28Xkt1Kqsrc%3D 16598373
134. E Seeman B Vellas C Benhamou JP Aquino J Semler JM Kaufman K Hoszowski AR Varela C Fiore K Brixen JY Reginster S Boonen 2006 Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older J Bone Miner Res 21 1113 1120 1:CAS:528:DC%2BD28XntlWqu7k%3D 16813532
135. E Seeman JP Devogelaer R Lorenc T Spector K Brixen A Balogh G Stucki JY Reginster 2008 Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia J Bone Miner Res 23 433 438 1:CAS:528: DC%2BD1cXjsl2itbo%3D 17997711
136. O Bruyere C Roux J Detilleux DO Slosman TD Spector P Fardellone K Brixen JP Devogelaer M Diaz-Curiel C Albanese JM Kaufman S Pors-Nielsen JY Reginster 2007 Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate J Clin Endocrinol Metab 92 3076 3081 1:CAS:528:DC%2BD2sXptl2hsb0%3D 17566094
137. Shea B, Wells G, Cranney A, Zytaruk N, Robinson V, Griffith L, Hamel C, Ortiz Z, Peterson J, Adachi J, Tugwell P, Guyatt G; Osteoporosis Methodology Group; Osteoporosis Research Advisory Group (2004) Calcium supplementation on bone loss in postmenopausal women. Cochrane Database Syst Rev CD004526
138. European Medicines Agency (EMEA) (2007) Question and answers on the safety of Protelos/Osseor (strontium ranelate) Ref. EMEA/534613/2007. Available via http://www.emea.europa.eu/humandocs/PDFs/EPAR/protelos/Protelos-Q&A- 53461307en.pdf. Accessed 1 Oct 2008
139. A Grosso I Douglas A Hingorani R MacAllister L Smeeth 2008 Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions Br J Clin Pharmacol 66 689 694 1:CAS:528:DC%2BD1cXhsVyntb7M 18754840
140. S Tas T Simonart 2003 Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update Dermatology 206 353 356 1:STN:280:DC%2BD3s3kslCmuw%3D%3D 12771485
141. M Sainz JG del Pozo LH Arias A Carvajal 2009 Strontium ranelate may cause alopecia BMJ 338 b1494 19386675
142. T Suda N Takahashi N Udagawa E Jimi MT Gillespie TJ Martin 1999 Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families Endocr Rev 20 345 357 1:CAS:528:DyaK1MXktVaqtLg%3D 10368775
143. J Li I Sarosi XQ Yan S Morony C Capparelli HL Tan S McCabe R Elliott S Scully G Van S Kaufman SC Juan Y Sun J Tarpley L Martin K Christensen J McCabe P Kostenuik H Hsu F Fletcher CR Dunstan DL Lacey WJ Boyle 2000 RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism Proc Natl Acad Sci U S A 97 1566 1571 1:CAS:528:DC%2BD3cXhsFCrsL4%3D 10677500
144. WS Simonet DL Lacey CR Dunstan M Kelley MS Chang R Luthy HQ Nguyen S Wooden L Bennett T Boone G Shimamoto M DeRose R Elliott A Colombero HL Tan G Trail J Sullivan E Davy N Bucay L Renshaw-Gegg TM Hughes D Hill W Pattison P Campbell S Sander G Van J Tarpley P Derby R Lee WJ Boyle 1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 89 309 319 1:CAS:528:DyaK2sXislCgtLc%3D 9108485
145. JJ Body P Greipp RE Coleman T Facon F Geurs JP Fermand JL Harousseau A Lipton X Marriette CD Williams A Nakanishi D Holloway CR Dunstan PJ Bekker 2003 A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases Cancer 97 887 892 12548591
146. PJ Bekker DL Holloway AS Rasmussen R Murphy SW Martin PT Leese GB Holmes CR Dunstan AM DePaoli 2004 A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women J Bone Miner Res 19 1059 1066 1:CAS:528:DC%2BD2cXlvFWrtr0%3D 15176987
147. LC Hofbauer S Khosla CR Dunstan DL Lacey TC Spelsberg BL Riggs 1999 Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells Endocrinology 140 4367 4370 1:CAS:528: DyaK1MXlslSqsLw%3D 10465311
148. G Eghbali-Fatourechi S Khosla A Sanyal WJ Boyle DL Lacey BL Riggs 2003 Role of RANK ligand in mediating increased bone resorption in early postmenopausal women J Clin Invest 111 1221 1230 1:CAS:528:DC%2BD3sXjtFCrs7g%3D 12697741
149. MR McClung EM Lewiecki SB Cohen MA Bolognese GC Woodson AH Moffett M Peacock PD Miller SN Lederman CH Chesnut D Lain AJ Kivitz DL Holloway C Zhang MC Peterson PJ Bekker 2006 Denosumab in postmenopausal women with low bone mineral density N Engl J Med 354 821 831 1:CAS:528:DC%2BD28Xhsl2gs7o%3D 16495394
150. EM Lewiecki PD Miller MR McClung SB Cohen MA Bolognese Y Liu A Wang S Siddhanti LA Fitzpatrick 2007 Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD J Bone Miner Res 22 1832 1841 1:CAS:528:DC%2BD2sXhsVyjtrjF 17708711
151. SR Cummings J San Martin MR McClung ES Siris R Eastell IR Reid, et al. 2009 Denosumab for prevention of fractures in postmenopausal women with osteoporosis New Engl J Med 361 756 765 1:CAS:528:DC%2BD1MXhtVWls7nF 19671655
152. JP Brown RL Prince C Deal RR Recker DP Kiel LH de Gregorio P Hadji LC Hofbauer JM Alvaro-Gracia H Wang M Austin RB Wagman R Newmark C Libanati J San Martin HG Bone 2009 Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial J Bone Miner Res 24 153 161 1:CAS:528:DC%2BD1MXht1yrtbc%3D 18767928
153. S Cummings R Eastell KE Ensrud DM Reid S Vukicevic A La Croix, et al. 2008 The effects of lasofoxifene on fractures and breast cancer: 3-year results from the PEARL trial J Bone Miner Res 23 S81 Abstr. 1288
154. R Downs AH Moffett A Ghosh DA Cox K Harper 2008 Effects of arzoxifene on bone turnover and safety in postmenopausal women with low bone mass: results from a 6-month phase 2 study J Bone Miner Res 23 S470 S471
155. SL Silverman C Christiansen HK Genant S Vukicevic JR Zanchetta TJ de Villiers GD Constantiene AA Chines 2008 Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial J Bone Miner Res 23 1923 1934 1:CAS:528:DC%2BD1MXosVylsbo%3D 18665787
156. GB Stroup MW Lark DF Veber A Bhattacharyya S Blake LC Dare KF Erhard SJ Hoffman IE James RW Marquis Y Ru JA Vasko-Moser BR Smith T Tomaszek M Gowen 2001 Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate J Bone Miner Res 16 1739 1746 1:CAS:528:DC%2BD3MXnsVKqtrc%3D 11585335
157. MR McClung H Bone E Cosman C Roux N Verbruggen C Hustad C DaSilva A Santora A Ince 2008 A randomized, double-blind, placebo-controlled study of odanacatib (MK-822) in the treatment of postmenopausal women with low bone mineral density: 24-month results J Bone Miner Res 23 S82
158. X Li MS Ominski KS Warmington S Morony J Gong J Cao Y Gao V Shalhoub B Tipton R Haldankar Q Chen A Winters T Boone Z Geng QT Niu HZ Ke PJ Kostenuik WS Simonet DL Lacey C Paszty 2009 Sclerostin antibody treatment increases bone formation, bone mass and bone strength in a rat model of postmenopausal osteoporosis J Bone Miner Res 24 578 588 1:CAS:528:DC%2BD1MXksF2lu7c%3D 19049336